EDAP TMS S.A. (EDAP)
| Market Cap | 241.92M |
| Revenue (ttm) | 65.80M |
| Net Income (ttm) | -19.82M |
| Shares Out | 37.10M |
| EPS (ttm) | -0.53 |
| PE Ratio | n/a |
| Forward PE | 38.02 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,930 |
| Open | 6.64 |
| Previous Close | 6.71 |
| Day's Range | 6.44 - 6.70 |
| 52-Week Range | 3.60 - 10.45 |
| Beta | 0.65 |
| Analysts | Strong Buy |
| Price Target | 14.00 (+113.58%) |
| Earnings Date | May 16, 2024 |
About EDAP
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST) segments. The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urolog... [Read more]
Financial Performance
In 2023, EDAP TMS's revenue was 60.42 million, an increase of 9.64% compared to the previous year's 55.11 million. Losses were -21.18 million, 622.1% more than in 2022.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for EDAP stock is "Strong Buy." The 12-month stock price forecast is $14.0, which is an increase of 113.58% from the latest price.
News
EDAP Announces Positive Final Results from the HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy During Plenary Session at the 119th American Urological Association (AUA) Annual Meeting
Final results demonstrate a significantly higher salvage treatment free survival rate (STFS) at 30 months of 89.6% in the HIFU-treated arm versus 86.2% in patients who underwent radical prostatectomy ...
EDAP to Announce First Quarter 2024 Financial Results on May 16, 2024
Company to host conference call and webcast on Thursday, May 16 th at 8:30am EDT LYON, France, May 2, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based ther...
EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual Meeting
LYON, France, April 23, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced that final results from the HIFI Study, the largest clinical trial ever conduc...
EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024
Company to host conference call and webcast on Wednesday, March 27 th at 8:30am EDT LYON, France, March 13, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-base...
EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
LYON, France, March 6, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled ...
EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis
Focal One HIFU has potential to address large market impacting thousands of women each year LYON, France, March 4, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapie...
EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2023 Revenues
LYON, France, February 29, 2024 - EDAP TMS SA (Nasdaq: EDAP), a global leader in robotic energy-based therapies, today announced preliminary unaudited fourth quarter and full-year 2023 revenues.
EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements
Company reports preliminary placement results of twelve Focal One Systems, inclusive of ten capital sales LYON, France, January 8, 2024 - EDAP TMS SA (Nasdaq: EDAP), (“EDAP”), the global leader in rob...
EDAP Appoints Ken Mobeck, Global Chief Financial Officer, and Francois Dietsch, Global Chief Accounting Officer
LYON, France, January 2, 2024 - EDAP TMS SA (Nasdaq: EDAP), (“EDAP”), the global leader in robotic energy-based therapies, today announced that the Company has appointed Ken Mobeck as its Chief Financ...
EDAP Announces Positive Opinion for Reimbursement from the French National Authority for Health (HAS) for HIFU treatment of Prostate Cancer
Represents Key Milestone Toward Universal Coverage for Focal One HIFU in France LYON, France, December 12, 2023 - EDAP TMS SA (Nasdaq: EDAP), (“EDAP”), the global leader in robotic energy-based therap...
EDAP Appoints Lance Willsey, M.S., M.D. to Board of Directors
LYON, France, December 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Lance Willsey, M.S., M.D...
EDAP Receives 2023 Industry Category Award from the French National Institute for Intellectual Property (INPI) for Its Therapeutic Ultrasound Technology
LYON, France, November 30, 2023 - EDAP TMS SA (Nasdaq: EDAP), (“EDAP”), the global leader in robotic energy-based therapies, today announced that is has received the Industry Category Award from the F...
EDAP to Present at Piper Sandler's 35th Annual Healthcare Conference
LYON, France, November 20, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is schedu...
EDAP Announces Third Quarter 2023 Financial Results
- Strong Q3 2023 U.S. Focal One ® HIFU procedure growth of +150% year-over-year - - Record nine months HIFU revenues reflecting growing demand - - Two additional Focal One systems already placed in th...
EDAP to Present at the Jefferies London Healthcare Conference
LYON, France, November 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is schedul...
EDAP TMS SA to Announce Third Quarter 2023 Financial Results on November 9, 2023
Company to host conference call and webcast on Thursday, November 9 th at 8:30am EDT LYON, France, October 26, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-b...
EDAP to Present at Morgan Stanley Annual Global Healthcare Conference and the H.C. Wainwright Annual Global Investment Conference
LYON, France, September 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is schedu...
EDAP Announces Second Quarter 2023 Financial Results
- Record second quarter and first half revenue s of EUR 14.3 million (USD 15 .5 million) and EUR 29.1 million (USD 31.5 million), respectively -
EDAP TMS SA to Announce Second Quarter 2023 Financial Results on August 24, 2023
- Company to host conference call and webcast on Thur sday, August 24 th at 8:30 am EDT -
EDAP Announces Reimbursement Approval in Switzerland for the Use of High-Intensity Focused Ultrasound (HIFU) in the Treatment of Prostate Cancer
LYON, France, July 26, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it has received reimbursement approval in Switzerla...
EDAP to Present at the Jefferies Healthcare Conference
LYON, France, May 24, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled t...
EDAP Announces First Quarter 2023 Financial Results
- Record first quarter revenue - - Positive results from two studies reconfirm safety and efficacy of Focal One - - Company to host conference call and webcast today, Wednesday, May 17 th at 8:30 am E...
EDAP to Announce First Quarter 2023 Financial Results on May 17, 2023
- Company to host conference call and webcast on Wednesday, May 1 7 th at 8:30 am EDT - LYON, France, May 3, 2023 - EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-base...
EDAP Announces Major Presence at Upcoming Annual Meeting of the American Urological Association (AUA)
Meeting to Showcase EDAP's Focal One ® Robotic High Intensity Focused Ultrasound (HIFU) Platform for the Management of Prostate Cancer LYON, France, April 21, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the ...
EDAP Announces Live Procedure Broadcast of Focal One High Intensity Focused Ultrasound (HIFU) to Global Clinical Audience
Leading Center Demonstrates Focal HIFU as a Tool in The Management of Prostate Cancer